Keck School Faculty

Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies LRRC4C, LHX5-AS1 and nominates ancestry-specific loci PTPRK , GRB14 , and KIAA0825 as novel risk loci for Alzheimer's disease: the Alzheimer's Disease Genetics Consortium medRxiv. 2023 Jul 08. . View in PubMed

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents World Psychiatry. 2023 Feb; 22(1):48-74. . View in PubMed

The small HDL particle hypothesis of Alzheimer's disease Alzheimers Dement. 2023 02; 19(2):391-404. . View in PubMed

A phase 1b randomized clinical trial of CT1812 to measure Aß oligomer displacement in Alzheimer's disease using an indwelling CSF catheter Transl Neurodegener. 2023 05 12; 12(1):24. . View in PubMed

Reliability of the NACC Telephone-administered Neuropsychological Battery (T-cog) and Montreal Cognitive Assessment for participants in the USC ADRC Alzheimers Dement (Amst). 2023 Jan-Mar; 15(1):e12406. . View in PubMed

Viewpoint: When It Comes to Lecanemab (and Donanemab), How Might We Think about 'Reasonable and Necessary'? J Prev Alzheimers Dis. 2023; 10(3):342-343.. View in PubMed

The relationship of history of psychiatric and substance use disorders on risk of dementia among racial and ethnic groups in the United States Front Psychiatry. 2023; 14:1165262. . View in PubMed

Alzheimer's and Dementia Guidelines and Tables Psychopharmacol Bull. 2023 07 12; 53(2):8-65. . View in PubMed

The human anti-ganglioside GM1 autoantibody response following traumatic and surgical central nervous system insults Neurosci Res. 2022 Aug; 181:105-114. . View in PubMed

The Safety of Pimavanserin for Parkinson's Disease and Efforts to Reduce Antipsychotics for People With Dementia Am J Psychiatry. 2022 08; 179(8):519-521. . View in PubMed

Nutrition state of science and dementia prevention: recommendations of the Nutrition for Dementia Prevention Working Group Lancet Healthy Longev. 2022 07; 3(7):e501-e512. . View in PubMed

Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report Alzheimers Dement. 2022 06; 18(6):1109-1118. . View in PubMed

Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria Alzheimers Dement. 2022 04; 18(4):810-823. . View in PubMed

Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race Alzheimers Dement. 2022 04; 18(4):867-868. . View in PubMed

Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists Alzheimers Dement. 2022 03; 18(3):478-497. . View in PubMed

The Current Landscape of Prevention Trials in Dementia Neurotherapeutics. 2022 01; 19(1):228-247. . View in PubMed

Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial J Prev Alzheimers Dis. 2022; 9(4):625-634. . View in PubMed

Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease Alzheimers Dement (N Y). 2022; 8(1):e12286. . View in PubMed

Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes Alzheimers Dement (N Y). 2022; 8(1):e12258. . View in PubMed

Editorial: Aducanumab Trials EMERGE But Don't ENGAGE J Prev Alzheimers Dis. 2022; 9(2):193-196. . View in PubMed

A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer's Disease J Prev Alzheimers Dis. 2022; 9(2):247-254. . View in PubMed

High Soluble Amyloid-ß42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations J Alzheimers Dis. 2022; 90(1):333-348. . View in PubMed

High cerebrospinal amyloid-ß 42 is associated with normal cognition in individuals with brain amyloidosis EClinicalMedicine. 2021 Aug; 38:100988. . View in PubMed

The efficacy of antidepressant medication and interpersonal psychotherapy for adult acute-phase depression: study protocol of a systematic review and meta-analysis of individual participant data BJPsych Open. 2021 Feb 19; 7(2):e56. . View in PubMed

The need to show minimum clinically important differences in Alzheimer's disease trials Lancet Psychiatry. 2021 11; 8(11):1013-1016. . View in PubMed

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification Alzheimers Dement. 2021 08; 17(8):1365-1382. . View in PubMed

Development of novel measures for Alzheimer's disease prevention trials (NoMAD) Contemp Clin Trials. 2021 07; 106:106425. . View in PubMed

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial Lancet Neurol. 2021 07; 20(7):537-547. . View in PubMed

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group Lancet Neurol. 2021 06; 20(6):484-496. . View in PubMed

Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults Brain Behav Immun. 2021 05; 94:299-307. . View in PubMed

Soluble Amyloid-ß Consumption in Alzheimer's Disease J Alzheimers Dis. 2021; 82(4):1403-1415. . View in PubMed

Value-Generating Exploratory Trials in Neurodegenerative Dementias Neurology. 2021 05 18; 96(20):944-954. . View in PubMed

Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study Alzheimers Res Ther. 2021 12 20; 13(1):201. . View in PubMed

Alzheimer's drugs: Does reducing amyloid work? Science. 2021 10 29; 374(6567):544-545.. View in PubMed

Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial EBioMedicine. 2020 Sep; 59:102883. . View in PubMed

A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid Alzheimers Dement. 2020 06; 16(6):821-830. . View in PubMed

APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline Nature. 2020 05; 581(7806):71-76. . View in PubMed

Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy Menopause. 2020 01; 27(1):57-65. . View in PubMed

Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial Alzheimers Dement (N Y). 2020; 6(1):e12107. . View in PubMed

Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid J Neurosci. 2020 10 28; 40(44):8573-8586. . View in PubMed

Pragmatic Trials and Repurposed Drugs for Alzheimer Disease JAMA Neurol. 2020 02 01; 77(2):162-163. . View in PubMed

Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time PLoS One. 2020; 15(2):e0228064. . View in PubMed

The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease Alzheimers Res Ther. 2020 03 02; 12(1):21. . View in PubMed

Response to peer commentaries: Composite cognitive and functional measures for early stage Alzheimer's disease trials Alzheimers Dement (Amst). 2020; 12(1):e12024. . View in PubMed

Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative J Alzheimers Dis. 2020; 76(2):691-701. . View in PubMed

Composite cognitive and functional measures for early stage Alzheimer's disease trials Alzheimers Dement (Amst). 2020; 12(1):e12017. . View in PubMed

Commentary: The EU/US Task Force's Future for Anti-Amyloid Trials: Faites Vos Jeux J Prev Alzheimers Dis. 2020; 7(3):199-200. . View in PubMed

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission Lancet. 2020 08 08; 396(10248):413-446. . View in PubMed

Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial JAMA Neurol. 2019 Nov 01; 76(11):1330-1339. . View in PubMed

Treatment Options for Agitation in Dementia Curr Treat Options Neurol. 2019 Jun 24; 21(7):30. . View in PubMed

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial Alzheimers Dement. 2019 11; 15(11):1427-1436. . View in PubMed

The risks and uses of dietary supplements Lancet Neurol. 2019 09; 18(9):814. . View in PubMed

Safety and feasibility of estrogen receptor-ß targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial Menopause. 2019 08; 26(8):874-884. . View in PubMed

A randomized clinical trial to evaluate home-based assessment of people over 75 years old Alzheimers Dement. 2019 05; 15(5):615-624. . View in PubMed

Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction Nat Med. 2019 02; 25(2):270-276. . View in PubMed

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need Alzheimers Dement. 2019 02; 15(2):292-312. . View in PubMed

Vascular dysfunction-The disregarded partner of Alzheimer's disease Alzheimers Dement. 2019 01; 15(1):158-167. . View in PubMed

Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial Neurology. 2019 10 08; 93(15):e1474-e1484. . View in PubMed

A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease Alzheimers Dement (N Y). 2019; 5:20-26. . View in PubMed

Evaluation of Medicare Claims Data as a Tool to Identify Dementia J Alzheimers Dis. 2019; 67(2):769-778. . View in PubMed

Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease Am J Alzheimers Dis Other Demen. 2018 11; 33(7):450-457. . View in PubMed

Precision pharmacology for Alzheimer's disease Pharmacol Res. 2018 04; 130:331-365. . View in PubMed

Pimavanserin for patients with Alzheimer's disease psychosis Lancet Neurol. 2018 03; 17(3):194-195. . View in PubMed

Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor ß-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women Menopause. 2018 02; 25(2):191-196. . View in PubMed

Analysis of shared heritability in common disorders of the brain Science. 2018 06 22; 360(6395). . View in PubMed

Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions Alzheimers Res Ther. 2018 01 15; 10(1):4. . View in PubMed

(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease Curr Alzheimer Res. 2018; 15(9):883-891. . View in PubMed

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort Alzheimers Dement (N Y). 2018; 4:150-160. . View in PubMed

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis JAMA Netw Open. 2018 11 02; 1(7):e184080. . View in PubMed

Dementia prevention, intervention, and care Lancet. 2017 Dec 16; 390(10113):2673-2734. . View in PubMed

Challenging Assumptions About African American Participation in Alzheimer Disease Trials Am J Geriatr Psychiatry. 2017 Oct; 25(10):1150-1159. . View in PubMed

Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E e4 Carriers: A Review JAMA Neurol. 2017 Mar 01; 74(3):339-347. . View in PubMed

Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease Alzheimers Res Ther. 2017 Feb 17; 9(1):10. . View in PubMed

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease Nat Genet. 2017 09; 49(9):1373-1384. . View in PubMed

Lessons from the Multidomain Alzheimer Preventive Trial Lancet Neurol. 2017 08; 16(8):585-586. . View in PubMed

Dementia research priorities-2 - Author's reply Lancet Neurol. 2017 03; 16(3):182. . View in PubMed

Dementia research priorities-1 - Author's reply Lancet Neurol. 2017 03; 16(3):181. . View in PubMed

Alzheimer's disease and other dementias: update on research Lancet Neurol. 2017 01; 16(1):4-5. . View in PubMed

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model Alzheimers Dement. 2017 01; 13(1):8-19. . View in PubMed

Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias Focus (Am Psychiatr Publ). 2017 Jan; 15(1):110-128. . View in PubMed

Characterizing Highly Benefited Patients in Randomized Clinical Trials Int J Biostat. 2017 05 20; 13(1). . View in PubMed

Preventing Dementia: Many Issues and Not Enough Time JAMA Neurol. 2017 05 01; 74(5):508-510. . View in PubMed

Reduce vascular risk to prevent dementia? Lancet. 2016 Aug 20; 388(10046):738-40.. View in PubMed

Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study Am J Psychiatry. 2016 May 01; 173(5):473-80. . View in PubMed

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial Am J Psychiatry. 2016 May 01; 173(5):465-72. . View in PubMed

Defeating Alzheimer's disease and other dementias: a priority for European science and society Lancet Neurol. 2016 Apr; 15(5):455-532. . View in PubMed

Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences J Geriatr Psychiatry Neurol. 2016 Mar; 29(2):59-64. . View in PubMed

Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease J Psychiatr Res. 2016 Mar; 74:17-21. . View in PubMed

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria Alzheimers Dement. 2016 Mar; 12(3):292-323. . View in PubMed

A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation J Pharmacokinet Pharmacodyn. 2016 Feb; 43(1):99-109. . View in PubMed

WHO's dementia research priorities: a prescription for failure? Lancet Neurol. 2016 11; 15(12):1202-1203.. View in PubMed

R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation Br J Clin Pharmacol. 2016 09; 82(3):784-92. . View in PubMed

Principal components analysis of agitation outcomes in Alzheimer's disease J Psychiatr Res. 2016 08; 79:4-7. . View in PubMed

Mortality risk in current and new antipsychotic Alzheimer's disease users: Large scale Japanese study Alzheimers Dement. 2016 07; 12(7):823-30. . View in PubMed

Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials Parkinsonism Relat Disord. 2016 07; 28:41-48. . View in PubMed

Accelerating stem cell trials for Alzheimer's disease Lancet Neurol. 2016 02; 15(2):219-230. . View in PubMed

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial Lancet. 2016 12 10; 388(10062):2873-2884. . View in PubMed

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease Alzheimers Res Ther. 2016 06 30; 8:25. . View in PubMed

Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials J Alzheimers Dis. 2016; 50(4):1205-15. . View in PubMed

Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial Int Psychogeriatr. 2015 Dec; 27(12):2059-67. . View in PubMed

Treatment changes among older patients with dementia treated with antipsychotics Int J Geriatr Psychiatry. 2015 Dec; 30(12):1238-49. . View in PubMed

Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease Am J Geriatr Psychiatry. 2015 Nov; 23(11):1127-33. . View in PubMed

Estimating Mortality Associated With Antipsychotics and Other Psychotropics--Reply JAMA Psychiatry. 2015 Oct; 72(10):1058. . View in PubMed

Introducing Alzheimer's & Dementia: Translational Research & Clinical Interventions, an open access journal of the Alzheimer's Association Alzheimers Dement (N Y). 2015 Jun; 1(1):91-93. . View in PubMed

Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment Alzheimers Dement (N Y). 2015 Jun; 1(1):63-71. . View in PubMed

Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change? Alzheimers Dement (N Y). 2015 Jun; 1(1):46-52.. View in PubMed

Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm JAMA Psychiatry. 2015 May; 72(5):438-45. . View in PubMed

Differences in Alzheimer disease clinical trial outcomes based on age of the participants Neurology. 2015 Mar 17; 84(11):1121-7. . View in PubMed

Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials Alzheimers Dement (Amst). 2015 Mar; 1(1):103-11. . View in PubMed

Rarity of the Alzheimer disease-protective APP A673T variant in the United States JAMA Neurol. 2015 Feb; 72(2):209-16. . View in PubMed

Adverse events and dropouts in Alzheimer's disease studies: what can we learn? Alzheimers Dement. 2015 Jan; 11(1):24-31.. View in PubMed

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future Expert Rev Neurother. 2015 Jan; 15(1):83-105. . View in PubMed

Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study JAMA Neurol. 2014 Nov; 71(11):1394-404. . View in PubMed

Idalopirdine for Alzheimer's disease: written in the stars Lancet Neurol. 2014 Nov; 13(11):1063-1065. . View in PubMed

2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. . View in PubMed

Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative Neurology. 2014 Jul 22; 83(4):364-73. . View in PubMed

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial Lancet Neurol. 2014 Jul; 13(7):676-85. . View in PubMed

Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease Alzheimers Dement. 2014 May; 10(3):349-59. . View in PubMed

Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study J Am Geriatr Soc. 2014 May; 62(5):985-8. . View in PubMed

Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease Alzheimers Dement. 2014 Mar; 10(2):247-50. . View in PubMed

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial JAMA. 2014 Feb 19; 311(7):682-91. . View in PubMed

A new roadmap for drug development for Alzheimer's disease Nat Rev Drug Discov. 2014 Feb; 13(2):156. . View in PubMed

Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial PLoS One. 2014; 9(6):e98426. . View in PubMed

Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24. . View in PubMed

Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future Alzheimers Dement. 2013 Sep; 9(5):602-8. . View in PubMed

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force Alzheimers Dement. 2013 Jul; 9(4):438-44. . View in PubMed

Moderators of outcome in late-life depression: a patient-level meta-analysis Am J Psychiatry. 2013 Jun; 170(6):651-9. . View in PubMed

Quantifying an amyloid ß model for Alzheimer's disease Lancet Neurol. 2013 Apr; 12(4):327-8. . View in PubMed

Alzheimer disease pharmacologic treatment and treatment research Continuum (Minneap Minn). 2013 Apr; 19(2 Dementia):339-57. . View in PubMed

Early intervention with an estrogen receptor ß-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease J Alzheimers Dis. 2013; 37(2):403-19. . View in PubMed

Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44. . View in PubMed

Ginkgo and AD: key negatives and lessons from GuidAge Lancet Neurol. 2012 Oct; 11(10):836-7. . View in PubMed

Novel late-onset Alzheimer disease loci variants associate with brain gene expression Neurology. 2012 Jul 17; 79(3):221-8. . View in PubMed

Caregiver burden, health utilities, and institutional service use in Alzheimer's disease Int J Geriatr Psychiatry. 2012 Apr; 27(4):382-93. . View in PubMed

Recruitment methods for United States Alzheimer disease prevention trials J Nutr Health Aging. 2012 Apr; 16(4):331-5. . View in PubMed

Discontinuing donepezil or starting memantine for Alzheimer's disease N Engl J Med. 2012 Mar 08; 366(10):957-9. . View in PubMed

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. . View in PubMed

Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. . View in PubMed

Biomarker positive and negative subjects in the ADNI cohort: clinical characterization Curr Alzheimer Res. 2012 12; 9(10):1135-41. . View in PubMed

Risk of mortality among individual antipsychotics in patients with dementia Am J Psychiatry. 2012 Jan; 169(1):71-9. . View in PubMed

Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease J Clin Psychiatry. 2012 Jan; 73(1):121-8. . View in PubMed

Citalopram for agitation in Alzheimer's disease: design and methods Alzheimers Dement. 2012; 8(2):121-30. . View in PubMed

Sertraline for the treatment of depression in Alzheimer disease: genetic influences J Geriatr Psychiatry Neurol. 2011 Dec; 24(4):222-8. . View in PubMed

Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress Free Radic Biol Med. 2011 Dec 01; 51(11):2007-17. . View in PubMed

Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study J Clin Pharmacol. 2011 Nov; 51(11):1587-91. . View in PubMed

Estrogen receptor ß-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause Menopause. 2011 Oct; 18(10):1131-42. . View in PubMed

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD Am J Psychiatry. 2011 Aug; 168(8):831-9. . View in PubMed

Lack of evidence for the efficacy of memantine in mild Alzheimer disease Arch Neurol. 2011 Aug; 68(8):991-8. . View in PubMed

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. . View in PubMed

Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons Mol Neurodegener. 2011 Jun 01; 6:37. . View in PubMed

Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)? Int J Geriatr Psychiatry. 2011 Jun; 26(6):573-83.. View in PubMed

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease Nat Genet. 2011 May; 43(5):436-41. . View in PubMed

Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. . View in PubMed

Trends in antipsychotic use in dementia 1999-2007 Arch Gen Psychiatry. 2011 Feb; 68(2):190-7. . View in PubMed

Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation Int Psychogeriatr. 2011 Feb; 23(1):44-53. . View in PubMed

Anti-aß therapeutics in Alzheimer's disease: the need for a paradigm shift Neuron. 2011 Jan 27; 69(2):203-13. . View in PubMed

Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative Arch Neurol. 2011 Jan; 68(1):58-66. . View in PubMed

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial J Clin Psychopharmacol. 2010 Dec; 30(6):683-7. . View in PubMed

Organising the language of Alzheimer's disease in light of biomarkers Lancet Neurol. 2010 Nov; 9(11):1044-5. . View in PubMed

Fixing Alzheimer disease trials by improving process and methods Curr Alzheimer Res. 2010 Nov; 7(7):564-5. . View in PubMed

Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates Am J Geriatr Psychiatry. 2010 Oct; 18(10):917-27. . View in PubMed

Caregiver burden, health utilities, and institutional service costs among community-dwelling patients with Alzheimer disease Alzheimer Dis Assoc Disord. 2010 Oct-Dec; 24(4):380-9. . View in PubMed

Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials Alzheimers Dement. 2010 Sep; 6(5):367-77. . View in PubMed

Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease Mol Neurodegener. 2010 Apr 13; 5:14. . View in PubMed

The potential and limits for clinical trials for early Alzheimer's disease and some recommendations J Nutr Health Aging. 2010 Apr; 14(4):295-8. . View in PubMed

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes Am J Geriatr Psychiatry. 2010 Apr; 18(4):332-40. . View in PubMed

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009 Alzheimers Dement. 2010 Mar; 6(2):89-97. . View in PubMed

Sertraline for the treatment of depression in Alzheimer disease Am J Geriatr Psychiatry. 2010 Feb; 18(2):136-45. . View in PubMed

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA. 2009 Dec 16; 302(23):2557-64. . View in PubMed

Current Alzheimer's disease clinical trials: methods and placebo outcomes Alzheimers Dement. 2009 Sep; 5(5):388-97. . View in PubMed

Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):260-7. . View in PubMed

Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis Int J Geriatr Psychiatry. 2009 May; 24(5):539-44. . View in PubMed

Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study Am J Psychiatry. 2009 May; 166(5):583-90. . View in PubMed

Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008" A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging. Alzheimers Dement. 2009 Mar; 5(2):172-9. . View in PubMed

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008 Alzheimers Dement. 2009 Mar; 5(2):85-92. . View in PubMed

The perils of Alzheimer's drug development Curr Alzheimer Res. 2009 Feb; 6(1):77-8. . View in PubMed

Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer's disease Int J Geriatr Psychiatry. 2009 Jan; 24(1):96-105. . View in PubMed

Sociodemographic and clinical correlates of utility scores in Alzheimer's disease Value Health. 2008 Dec; 11(7):1120-30. . View in PubMed

Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity Mol Brain. 2008 Nov 21; 1:17. . View in PubMed

Ginkgo biloba extract and preventing Alzheimer disease JAMA. 2008 Nov 19; 300(19):2306-8. . View in PubMed

Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia Schizophr Res. 2008 Nov; 106(1):33-41. . View in PubMed

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA. 2008 Oct 15; 300(15):1774-83. . View in PubMed

Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence Am J Geriatr Psychiatry. 2008 Jul; 16(7):558-67. . View in PubMed

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial Am J Psychiatry. 2008 Jul; 165(7):844-54. . View in PubMed

Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria Am J Geriatr Psychiatry. 2008 Jun; 16(6):469-77. . View in PubMed

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium Alzheimers Dement. 2008 May; 4(3):156-63. . View in PubMed

Does donepezil improve executive function in patients with CADASIL? Lancet Neurol. 2008 Apr; 7(4):287-9.. View in PubMed

Sex, race, and smoking impact olanzapine exposure J Clin Pharmacol. 2008 Feb; 48(2):157-65. . View in PubMed

Prevention therapeutics of dementia Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S122-30. . View in PubMed

American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementiasSecond edition. Am J Psychiatry. 2007 Dec; 164(12 Suppl):5-56. . View in PubMed

Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease Arch Gen Psychiatry. 2007 Nov; 64(11):1259-68. . View in PubMed

Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials Lancet Neurol. 2007 Sep; 6(9):782-92. . View in PubMed

Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease? Curr Alzheimer Res. 2007 Jul; 4(3):273-6.. View in PubMed

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics Curr Alzheimer Res. 2007 Jul; 4(3):325-35. . View in PubMed

Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease" Wuthering forest plots: distinguishing the forest from the plots. Alzheimers Dement. 2007 Jan; 3(1):18-20. . View in PubMed

Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment Mitochondrion. 2006 Dec; 6(6):323-30. . View in PubMed

Design of Depression in Alzheimer's Disease Study-2 Am J Geriatr Psychiatry. 2006 Nov; 14(11):920-30. . View in PubMed

Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice Brain Res. 2006 Oct 20; 1116(1):194-200. . View in PubMed

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease N Engl J Med. 2006 Oct 12; 355(15):1525-38. . View in PubMed

ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S124-38. . View in PubMed

Open-label extension studies and misinformation Arch Neurol. 2006 Jul; 63(7):1036; author reply 1036-7. . View in PubMed

Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91. . View in PubMed

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials Am J Geriatr Psychiatry. 2006 Mar; 14(3):191-210. . View in PubMed

The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London? Int J Geriatr Psychiatry. 2006 Jan; 21(1):9-13.. View in PubMed

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type Curr Alzheimer Res. 2005 Dec; 2(5):541-51. . View in PubMed

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials JAMA. 2005 Oct 19; 294(15):1934-43. . View in PubMed

Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):279-83. . View in PubMed

Mild cognitive impairment Am J Geriatr Psychiatry. 2005 Aug; 13(8):629-32. . View in PubMed

Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration's systematic review Alzheimers Dement. 2005 Jul; 1(1):67-71. . View in PubMed

Symptoms of late-life depression: frequency and change during treatment Am J Geriatr Psychiatry. 2005 Jun; 13(6):520-6. . View in PubMed

Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease' Int J Geriatr Psychiatry. 2005 Feb; 20(2):119-27. . View in PubMed

Recognizing and responding to atypical antipsychotic side effects J Am Med Dir Assoc. 2004 Jul-Aug; 5(4 Suppl):H7-10. . View in PubMed

AD2000: donepezil in Alzheimer's disease Lancet. 2004 Jun 26; 363(9427):2100-1. . View in PubMed

Estrogen and dementia: insights from the Women's Health Initiative Memory Study JAMA. 2004 Jun 23; 291(24):3005-7. . View in PubMed

Delay in nursing home placement with donepezil J Am Geriatr Soc. 2004 Jun; 52(6):1024-6; author reply 1026-7. . View in PubMed

Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Evid Based Ment Health. 2004 May; 7(2):47. . View in PubMed

Psychosis of Alzheimer's disease: clinical characteristics and history J Psychiatr Res. 2004 Jan; 38(1):105-11. . View in PubMed

Evidence-based practices in geriatric mental health care: an overview of systematic reviews and meta-analyses Psychiatr Clin North Am. 2003 Dec; 26(4):971-90x-xi. . View in PubMed

Cholinesterase inhibitors for vascular dementia? Lancet Neurol. 2003 Nov; 2(11):658-9.. View in PubMed

Efficacy of controlled-release paroxetine in the treatment of late-life depression J Clin Psychiatry. 2003 Sep; 64(9):1065-74. . View in PubMed

Choosing treatment for Alzheimer's patients and their caregivers Geriatrics. 2003 Aug; 58 Suppl 1:3-1823; quiz 19-22. . View in PubMed

An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression Am J Psychiatry. 2003 Jul; 160(7):1277-85. . View in PubMed

Psychosis of Alzheimer disease: validity of the construct and response to risperidone Am J Geriatr Psychiatry. 2003 Jul-Aug; 11(4):414-25. . View in PubMed

Cholinesterase inhibitors for Alzheimer disease JAMA. 2003 May 14; 289(18):2359-60; author reply 2360-1. . View in PubMed

A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease Curr Drug Targets. 2003 Feb; 4(2):97-112. . View in PubMed

Provisional diagnostic criteria for depression of Alzheimer's disease: description and review Expert Rev Neurother. 2003 01; 3(1):99-106. . View in PubMed

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial Schizophr Bull. 2003; 29(1):57-72. . View in PubMed

The increasing power of placebos in trials of antidepressants JAMA. 2002 Jul 24-31; 288(4):450. . View in PubMed

Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background Am J Geriatr Psychiatry. 2002 Mar-Apr; 10(2):129-41. . View in PubMed

Provisional diagnostic criteria for depression of Alzheimer disease Am J Geriatr Psychiatry. 2002 Mar-Apr; 10(2):125-8. . View in PubMed

Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer's disease J Neuropsychiatry Clin Neurosci. 2002; 14(3):303-10. . View in PubMed

Treatment of Alzheimer's disease with cholinesterase inhibitors Clin Geriatr Med. 2001 May; 17(2):337-58. . View in PubMed

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology Am J Geriatr Psychiatry. 2001; 9(4):346-60. . View in PubMed

Antidepressant Treatment of Very Old Patients Am J Geriatr Psychiatry. 1993 Winter; 1(1):21-29. . View in PubMed